By Michael Dabaie

 

Moderna Inc. said it filed for authorization of its Covid-19 vaccine with Health Canada to include children ages 6 to 11.

The biotechnology company said it submitted for authorization with Health Canada for the evaluation of a 50 microgram two-dose series of Spikevax in children ages 6 to 11 years.

Moderna earlier this month filed to expand the conditional marketing authorization for its Covid-19 vaccine in the European Union to include children aged 6 to 11.

The Phase 2/3 KidCOVE study of the vaccine in pediatric population ages 6 months to under 12 years is continuing. Moderna recently shared data from the KidCOVE study in children 6 years to 11. Vaccine efficacy of 100% using the Phase 3 COVE study primary case definition for Covid-19 was observed two weeks after the first dose of Spikevax at the 50 ug dose level, the company said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

November 17, 2021 08:54 ET (13:54 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Moderna Charts.